Pictured: Entrance to Moderna's office in Massachusetts/iStock, hapabapa

图为马萨诸塞州/伊斯托克市摩德纳办公室入口

Moderna has backed out of its gene editing deal with Metagenomi, handing back full global rights to the primary hyperoxaluria type 1 program and other related technologies, including base editors and RNA-mediated integration systems.

Moderna已经退出了与Metagenomi的基因编辑协议，将全部全球权利移交给了原发性高草酸尿症1型计划和其他相关技术，包括基础编辑器和RNA介导的整合系统。

Metagenomi in Wednesday’s announcement said that the partners have “mutually agreed” to terminate the agreement, but that the decision came after a “strategic prioritization” by Moderna. However, the mRNA-focused biopharma company will remain a shareholder of Metagenomi.

梅塔吉诺米在周三的声明中表示，合作伙伴“相互同意”终止协议，但这一决定是在Moderna“战略优先”之后做出的。然而，专注于mRNA的生物制药公司仍将是Metagenomi的股东。

Despite losing a powerhouse partner, Metagenomi CEO Brian Thomas said in a statement that the biotech is “pleased to regain full control of the development of base editing technology” and its RNA-mediated integration systems (RIGS), which will allow the company to harness these platforms to develop treatments in “areas of significant need, such as Alpha-1 antitrypsin deficiency and Wilson’s disease.”.

尽管失去了一个强大的合作伙伴，Metagenomi首席执行官布赖恩·托马斯（BrianThomas）在一份声明中表示，该生物技术公司“很高兴重新完全控制基础编辑技术的发展”及其RNA介导的整合系统（RIGS），这将使该公司能够利用这些平台开发“重要需求领域的治疗方法，如α-1抗胰蛋白酶缺乏症和威尔逊氏病”。

Metagenomi is capable of advancing programs on its own, Thomas said, adding that the biotech has over the years built up its footprint and talent base, as well as “leveraged significant private and public funding to greatly expand our gene editing toolbox, and established in-house manufacturing.”

托马斯说，Metagenomi能够自行推进项目，并补充说，多年来，该生物技术已经建立了自己的足迹和人才基础，并且“利用大量私人和公共资金，大大扩展了我们的基因编辑工具箱，并建立了内部制造。”

Moderna and Metagenomi inked the gene editing partnership in 2021, combining the former’s mRNA platform with the latter’s gene editing expertise to develop in vivo human therapies.

Moderna和Metagenomi于2021年建立了基因编辑合作伙伴关系，将前者的mRNA平台与后者的基因编辑专业知识相结合，开发体内人类疗法。

At the time, the partners did not disclose the specific financial details of the deal, though subsequent SEC filings showed that Metagenomi could have potentially generated more than $3 billion from the agreement, plus an upfront payment and royalties. As of December 31, 2023, the biotech had secured $49.6 million from the partnership..

当时，合伙人没有透露交易的具体财务细节，尽管随后的SEC文件显示，Metagenomi可能从该协议中产生超过30亿美元的收益，外加预付款和版税。截至2023年12月31日，该生物技术公司已从该合伙企业获得4960万美元。。

In February 2024, Metagenomi debuted on the Nasdaq Global Select Market with a nearly $94 million initial public offering (IPO). The biotech’s shares cratered 31% the following day, highlighting the problems faced by earlier-stage companies that go public.

2024年2月，Metagenomi以近9400万美元的首次公开募股（IPO）在纳斯达克全球精选市场首次亮相。第二天，这家生物技术公司的股价暴跌31%，突显了上市初期公司面临的问题。

Some of the market’s apprehension over Metagenomi’s IPO could be attributed to the fact that it has no candidates in the clinic. Instead, the biotech has focused on creating what it brands as “the most diverse genome editing toolbox” to target various genetic conditions.

市场对Metagenomi首次公开募股的一些担忧可能是由于该公司在临床上没有候选人。相反，这家生物技术公司专注于创建其品牌为“最多样化的基因组编辑工具箱”，以针对各种遗传条件。

For Moderna, the discontinuation of the Metagenomi partnership comes after it suffered more than $1 billion in losses and write-downs linked to low demand for its vaccine and cancelled orders for Africa. The company has in turn suspended the construction of an mRNA manufacturing facility in Kenya while it assesses the demand for its vaccines..

对于Moderna来说，Metagenomi合作伙伴关系的终止是在它遭受了超过10亿美元的损失和减记之后，这与它的疫苗需求低和取消了对非洲的订单有关。该公司在评估疫苗需求时，又暂停了在肯尼亚建造mRNA生产设施。。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾马尼拉。在LinkedIn上联系他，或发电子邮件给他tristan@tristanmanalac.com或tristan.manalac@biospace.com.